Newsroom | Servier https://servier.mediaroom.com/ Servier announces top-line results from the pivotal study for sevasemten in Becker muscular dystrophy https://servier.mediaroom.com/news-releases?item=122498 Tue, 03 Nov 2026 08:10:00 -0500 https://servier.mediaroom.com/news-releases?item=122498 Servier Announces First Patients Dosed in Pivotal Phase 2 EMBLEM-1 Cohort Evaluating Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma https://servier.mediaroom.com/2026-10-19-Servier-Announces-First-Patients-Dosed-in-Pivotal-Phase-2-EMBLEM-1-Cohort-Evaluating-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma Mon, 19 Oct 2026 08:00:00 -0400 https://servier.mediaroom.com/2026-10-19-Servier-Announces-First-Patients-Dosed-in-Pivotal-Phase-2-EMBLEM-1-Cohort-Evaluating-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma Servier’s VORANIGO® (vorasidenib) and TIBSOVO® (ivosidenib) Nominated for 2026 Prix Galien International Awards https://servier.mediaroom.com/2026-08-18-Serviers-VORANIGO-R-vorasidenib-and-TIBSOVO-R-ivosidenib-Nominated-for-2026-Prix-Galien-International-Awards Tue, 18 Aug 2026 07:59:00 -0400 https://servier.mediaroom.com/2026-08-18-Serviers-VORANIGO-R-vorasidenib-and-TIBSOVO-R-ivosidenib-Nominated-for-2026-Prix-Galien-International-Awards Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business https://servier.mediaroom.com/news-releases?item=122495 Mon, 13 Jul 2026 08:30:00 -0400 https://servier.mediaroom.com/news-releases?item=122495 Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio https://servier.mediaroom.com/2026-06-26-Servier-Presentations-at-ISPNO-2026-Highlight-Neuro-Oncology-Leadership-and-Expanding-Glioma-Portfolio Fri, 26 Jun 2026 09:05:00 -0400 https://servier.mediaroom.com/2026-06-26-Servier-Presentations-at-ISPNO-2026-Highlight-Neuro-Oncology-Leadership-and-Expanding-Glioma-Portfolio Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S. https://servier.mediaroom.com/2026-06-25-Servier-Announces-First-Patient-Enrolled-in-Phase-Ib-II-Study-for-the-Treatment-of-a-Rare-Pediatric-Epilepsy-Syndrome-in-the-U-S Thu, 25 Jun 2026 08:30:00 -0400 https://servier.mediaroom.com/2026-06-25-Servier-Announces-First-Patient-Enrolled-in-Phase-Ib-II-Study-for-the-Treatment-of-a-Rare-Pediatric-Epilepsy-Syndrome-in-the-U-S Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026 https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026 Mon, 01 Jun 2026 09:24:00 -0400 https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026 Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business https://servier.mediaroom.com/news-releases?item=122491 Mon, 01 Jun 2026 07:35:00 -0400 https://servier.mediaroom.com/news-releases?item=122491 Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026 https://servier.mediaroom.com/2026-05-31-Servier-to-Present-Extended-Follow-Up-Results-from-the-Phase-3-INDIGO-Trial-Showing-Durable-and-Sustained-Treatment-Benefits-of-VORANIGO-R-vorasidenib-at-ASCO-2026 Sun, 31 May 2026 17:36:00 -0400 https://servier.mediaroom.com/2026-05-31-Servier-to-Present-Extended-Follow-Up-Results-from-the-Phase-3-INDIGO-Trial-Showing-Durable-and-Sustained-Treatment-Benefits-of-VORANIGO-R-vorasidenib-at-ASCO-2026 Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio https://servier.mediaroom.com/2026-05-21-Servier-Presentations-at-ASCO-2026-Spotlight-Expanding-Rare-Oncology-Portfolio Thu, 21 May 2026 17:00:00 -0400 https://servier.mediaroom.com/2026-05-21-Servier-Presentations-at-ASCO-2026-Spotlight-Expanding-Rare-Oncology-Portfolio